Department of Urology, Sumitomo Hospital, Kita-ku, Osaka, 530-0005, Japan.
Med Oncol. 2011 Jun;28(2):463-5. doi: 10.1007/s12032-010-9479-2. Epub 2010 Mar 19.
Sorafenib is a multikinase inhibitor that is used for the treatment of metastatic renal-cell carcinoma. We report the case of a patient with painless acute pancreatitis associated with sorafenib treatment. The patient was a 71-year-old man who had undergone surgery for left renal carcinoma and tumor thrombus in the inferior vena cava and right atrium (IVC-RA). After a follow-up period of 3 years, he developed right adrenal metastasis and received interferon (IFN)-alpha treatment. One year later, progression of the adrenal metastasis was observed, and he was admitted to a hospital for treatment with sorafenib, which was administered at a dose of 800 mg/day. Two weeks later, he developed painless acute pancreatitis associated with sorafenib treatment. Thereafter, sorafenib treatment was discontinued, and he was treated with conservative therapy. Three weeks later, he was discharged. Even though painless acute pancreatitis associated with sorafenib treatment is rare, the possible development of painless acute pancreatitis in patients undergoing sorafenib treatment must be kept in mind.
索拉非尼是一种多激酶抑制剂，用于治疗转移性肾细胞癌。我们报告了一例与索拉非尼治疗相关的无痛性急性胰腺炎患者。该患者为 71 岁男性，曾因左肾癌和下腔静脉-右心房（IVC-RA）肿瘤血栓接受手术治疗。随访 3 年后，他出现右肾上腺转移，并接受干扰素（IFN）-α治疗。一年后，观察到肾上腺转移进展，他因接受索拉非尼治疗而入院，剂量为 800 mg/天。两周后，他出现与索拉非尼治疗相关的无痛性急性胰腺炎。此后，停止索拉非尼治疗，并采用保守治疗。三周后，他出院。尽管与索拉非尼治疗相关的无痛性急性胰腺炎很少见，但在接受索拉非尼治疗的患者中可能会出现无痛性急性胰腺炎，必须牢记这一点。
